GlassScriptPhysician profile
Erika Green
NPI 1649443722
$6,747.53
in general payments reported to CMS, 2019-2025
48 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,350 · 2022: $1,950 · 2023: $1,802 · 2024: $1,645.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,447.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,447.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,284.90 | 2021-2024 | |
| Lilly USA, LLC | $820.86 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $812.25 | 2021-2024 | Farxiga, Airsupra, Flumist Quadrivalent |
| Novo Nordisk INC | $489.82 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $327.02 | 2021-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $268.64 | 2022-2024 | |
| Otsuka America Pharmaceutical, INC. | $255.12 | 2022-2024 | Rexulti, Nuedexta |
| Amgen INC. | $227.27 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $177.21 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.02 | 2021-2024 | Jardiance |
| Pfizer INC. | $143.30 | 2022-2024 | |
| Medtronic, INC. | $138.59 | 2021-2024 | Intellis Adaptivestim |
| E.R. Squibb & Sons, L.L.C. | $130.87 | 2021-2023 | Eliquis |
| Janssen Pharmaceuticals, INC | $128.84 | 2021-2022 | |
| Amarin Pharma, INC. | $115.95 | 2021-2022 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erika Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.